A general practice assessment of Locabiotal in the treatment of upper respiratory tract infections.
An open clinical trial of Locabiotal, in which the antibiotic, fusafungine, is presented in a micronized aerosol was performed in general practice. One hundred and ten patients suffering from upper respiratory infections without associated hyperpyrexia or toxic symptoms were treated for 7 days. There was a marked improvement in the symptoms rated during the first 48 hours. After the full course of treatment 37 patients regarded its effect as excellent and 48 as good.
D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003139:Common Cold / Q000188:drug therapy; D047630:Depsipeptides; D005260:Female; D006801:Humans; D007827:Laryngitis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010612:Pharyngitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012220:Rhinitis / Q000188:drug therapy
D000336:Aerosols; D000900:Anti-Bacterial Agents; D047630:Depsipeptides; C014001:fusafungin